MCL1 and non-small cell lung carcinoma: Moreover, tyrosine kinase inhibitors (TKIs) give rise to GSK3β-dependent phosphorylation of MCL-1, translocation of MCL-1 to nucleus, as well as FBXW7-mediated degradation through targeting PI3K/AKT signaling, which overcome the resistance to targeted therapy in non-small cell lung cancer (NSCLC) (60).